Healthcare Decliners: ACADIA Pharmaceuticals (NASDAQ:ACAD), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals Inc (NYSEMKT:INO), NPS Pharmaceuticals (NASDAQ:NPSP)


ACADIA Pharmaceuticals (NASDAQ:ACAD) CEO Uli Hacksell sold 20,000 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $23.10, for a total transaction of $462,000.00. The sale was disclosed in a document filed with the SEC. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) weekly performance is -4.56%. On last trading day company shares ended up $21.56. Analysts mean target price for the company is $32.67. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average is 2.08%.

Novavax (NASDAQ:NVAX) SVP John Trizzino acquired 16,500 shares of Novavax stock in a transaction dated Monday, June 16th. The shares were purchased at an average cost of $4.51 per share, for a total transaction of $74,415.00. Following the purchase, the senior vice president now directly owns 16,500 shares in the company, valued at approximately $74,415. The purchase was disclosed in a document filed with the Securities & Exchange Commission. Novavax, Inc. (NASDAQ:NVAX) shares fell -8.44% in last trading session and ended the day on $4.34. NVAX Gross Margin is 61.20% and its return on assets is -28.20%. Novavax, Inc. (NASDAQ:NVAX) quarterly performance is 5.85%.

Inovio Pharmaceuticals, Inc. (nyse mkt:INO) announced that it has been added to the Russell Global, Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Approximately $5.2 trillion in assets are currently benchmarked to Russell Indexes. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares moved down -6.68% in last trading session and was closed at $10.06, while trading in range of $9.55-$10.80. Inovio Pharmaceuticals Inc (NYSEMKT:INO) year to date performance is -13.28%.

NPS Pharmaceuticals (NPSP) announced that the label of its sole marketed product, Gattex, has been updated by the FDA. The U.S. label of the drug now includes long-term data from STEPS 2 (n=88) — the two-year open-label extension of the 24-week phase III international STEPS study. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) ended the last trading day at $29.79. Company weekly volatility is calculated as 4.61% and price to cash ratio as 18.05. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) showed a negative weekly performance of -9.86%.

Leave a Reply

Your email address will not be published. Required fields are marked *